首页 › 子宫内膜癌 › 加利福尼亚州 › San Francisco
San Francisco CA 子宫内膜癌临床试验
14项针对 子宫内膜癌的研究正在 San Francisco及周边约 30 英里内的站点招募参与者。打开研究详情可查看入选标准及联系研究团队的方式。
官方研究文本（英文）
正在为研究招募参与者？将此页面置顶展示 — $99 / 30天 →
Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
招募中3 期
- Kaiser Permanente-San Francisco, San Francisco
Distance-Based Exercise to Preserve Function and Prevent Disability
招募中
- Kaiser Permanente-San Francisco, San Francisco
Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer
招募中3 期
- CPMC Research Institute, San Francisco
Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
招募中1 期
- University of California, San Francisco
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
招募中1/2 期
- UCSF Medical Center-Mission Bay, San Francisco
FOG-001 in Locally Advanced or Metastatic Solid Tumors
招募中1/2 期
- University of California San Francisco, Helen Diller Family Comprehensive Cancer Center, San Francisco
A Study of DM002 in Patients With Advanced Solid Tumors
招募中1/2 期
- University of California San Francisco Cancer Center, San Francisco
Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
招募中2 期
- 014, San Francisco
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
招募中1/2 期
- UCSF Medical Center at Mission Bay, San Francisco
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
招募中1/2 期
- UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco
Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
招募中1/2 期
- UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco
Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial Cancer
招募中2 期
- University of California, San Francisco (UCSF), San Francisco
Zanzalintinib in Combination With Paclitaxel in Recurrent High Grade Uterine Cancer
招募中1 期
- University of California, San Francisco, San Francisco
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
招募中观察性研究
- Massive Bio SYNERGY-AI site, San Francisco
其他城市的 子宫内膜癌试验
- Houston, TX68 项研究
- New York City, NY52 项研究
- Boston, MA50 项研究
- Arlington, VA39 项研究
- Nashville, TN38 项研究
- Los Angeles, CA34 项研究
- St. Louis, MO29 项研究
- Philadelphia, PA28 项研究
- San Antonio, TX27 项研究
- Columbus, OH25 项研究
- Chicago, IL25 项研究
- Oklahoma City, OK25 项研究
San Francisco的其他研究
- 前列腺癌45 项研究
- 乳腺癌43 项研究
- 非小细胞肺癌36 项研究
- 癌症（所有类型）35 项研究
- 心力衰竭29 项研究
- 转移性癌症28 项研究
- 肺癌22 项研究
- 黑色素瘤22 项研究
- 胰腺癌20 项研究
- 卵巢癌19 项研究
- 结直肠癌18 项研究
- 心血管疾病18 项研究
数据来自 ClinicalTrials.gov，检索日期：2026年10月6日。每项研究自行设定入选标准，由研究团队决定谁能参与。